EMEA: Contrast Agents Associated With Kidney Risk

Manufacturers of contrast agents containing gadolinium that are used for magnetic resonance scans are being asked to revise the drug labeling to warn of the risk of developing nephrogenic systemic fibrosis (NSF), the European Medicines Agency (EMEA) says. The recommendation was issued by the agency’s Committee for Medicinal Products for Human Use after its review of the association between the drugs and NSF, a rare condition characterized by thickening of connective tissue in the skin, joints, muscles and internal organs in patients with severe kidney problems.
International Pharmaceutical Regulatory Monitor